SCYNEXIS, Inc.
SCYNEXIS, Inc. scores highest on Torque (65) and lowest on Earnings (28). Its PosiPenta is 41.29 out of 100, around the middle of similar companies.
On the Penta Grid this week, SCYNEXIS, Inc. is Grid #491 of 837 in the Healthcare sector in United States, and Grid #2,749 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| SCYNEXIS, Inc. | 41.29 | 45 | 28 | 30 | 65 | 38 |
| Harvard Bioscience, Inc. | 43.40 | 14 | 58 | 88 | 18 | 40 |
| Dogwood Therapeutics, Inc. | 52.52 | 91 | 44 | 15 | 66 | 47 |
| Elutia Inc. | 40.08 | 26 | 34 | 59 | 38 | 44 |
| Nephros, Inc. | 56.23 | 47 | 63 | 56 | 71 | 44 |
| Instil Bio, Inc. | 31.50 | 47 | 10 | 23 | 42 | 35 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.12 |
| P/B ratio | 0.55 |
EEarnings
| Trailing EPS | ₹-84.30 |
| Forward EPS | ₹-219.27 |
NNitro
| Price | 347.60 |
| 52-week high | 863.80 |
| 52-week low | 334.34 |
| Fall from 52-week high | 59.8% |
TTorque
| Return on equity (ROE) | -18.38% |
| Debt-to-equity | 0.03 |
AAnchor
| Beta (price swings) | 1.06 |
| Market cap | ₹345 Cr |
| Insider holding | 2.05% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is SCYNEXIS, Inc.'s PosiPenta score?
SCYNEXIS, Inc.'s PosiPenta is 41.29 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does SCYNEXIS, Inc. stand on the Penta Grid?
On the Penta Grid this week, SCYNEXIS, Inc. is Grid #491 of 837 in the Healthcare sector in United States, and Grid #2,749 of 4,000 in United States.
Which PosiPenta pillar is strongest for SCYNEXIS, Inc.?
Torque (durability), with a score of 65 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for SCYNEXIS, Inc.?
Earnings (growth), with a score of 28 out of 100: weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.